Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis.
about
Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological SocietyConcordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targetsRegulation of B lymphocytes and plasma cells by innate immune mechanisms and stromal cells in rheumatoid arthritis.Pathogenesis of ANCA-associated vasculitisArtesunate abolishes germinal center B cells and inhibits autoimmune arthritisB cell depletion reduces the number of autoreactive T helper cells and prevents glucose-6-phosphate isomerase-induced arthritisGut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cellsB cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells.Simultaneous assessment of rotavirus-specific memory B cells and serological memory after B cell depletion therapy with rituximab.TLR9 Ligand (CpG Oligodeoxynucleotide) Induces CLL B-Cells to Differentiate into CD20(+) Antibody-Secreting Cells.Mycophenolic acid counteracts B cell proliferation and plasmablast formation in patients with systemic lupus erythematosusB cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas.Emerging Role of the Spleen in the Pharmacokinetics of Monoclonal Antibodies, Nanoparticles and Exosomes.Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients.How advances in immunology provide insight into improving vaccine efficacy.Altered B cell signalling in autoimmunity.Pathogenesis of ANCA-associated vasculitis.Human T-follicular helper and T-follicular regulatory cell maintenance is independent of germinal centersTransient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin: immunologic effects and efficacy in NOD mice.Autoimmunity contributes to nociceptive sensitization in a mouse model of complex regional pain syndrome.Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model.Rituximab selectively suppresses specific islet antibodies.Long-term maintenance of polysaccharide-specific antibodies by IgM-secreting cellsB-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance TreatmentBortezomib Plus Continuous B Cell Depletion Results in Sustained Plasma Cell Depletion and Amelioration of Lupus Nephritis in NZB/W F1 Mice.Addition of an indoleamine 2,3,-dioxygenase inhibitor to B cell-depletion therapy blocks autoreactive B cell activation and recurrence of arthritis in K/BxN mice.Gut Microbiota Drive Autoimmune Arthritis by Promoting Differentiation and Migration of Peyer's Patch T Follicular Helper Cells.Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome.Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial.B cells establish, but do not maintain, long-lived murine anti-peanut IgE(a).B Cell in Autoimmune Diseases.Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.B cells as effectors and regulators of sex-biased arthritis.Detection and isolation of auto-reactive human antibodies from primary B cellsAutoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis.Of mice and men: how animal models advance our understanding of T-cell function in RA.Long-term B cell depletion in murine lupus eliminates autoantibody-secreting cells and is associated with alterations in the kidney plasma cell niche.Immunologic and metabolic biomarkers of β-cell destruction in the diagnosis of type 1 diabetes.B cells and antibodies in multiple sclerosis pathogenesis and therapy.Targeting monocytes/macrophages in the treatment of rheumatoid arthritis.
P2860
Q26765172-AD9246E1-D67C-401D-8E04-560A913BFD4FQ26830569-708B9381-A703-4CD8-ABF5-3A232EB3DE05Q27686770-8F41F04C-F0F7-405F-98F5-B56AD7753850Q28390438-22E0890F-2503-489A-BD80-C3A468E43271Q28541811-130BA360-FE6F-46BD-833B-CD95E576C8A6Q28740546-C815E7BC-5C4C-4B50-B337-0573330440A7Q29614271-F2699CB2-02A0-4562-9E32-35D802765E66Q33404838-AFD18E35-F264-49CF-85A5-8D29AD098583Q33599297-712035B6-5FCE-4756-94D6-4DAC5AC023D4Q33760295-27DA3996-81A2-40E4-9CB7-9CE2C187D3B7Q33766270-0151D743-04C1-49F2-BE8D-99D63C57B4DCQ33776937-0829B72B-AF69-480E-AF30-91B2B11BE227Q33838871-0C2D3766-CDE7-4E94-91AA-8747A1F52299Q33849373-63529B3C-423F-45C2-BD8B-0FE5BAE519FEQ33896995-7E1F8F18-C7C8-4129-9D44-C262031A752DQ33924642-8EEBE727-5E0B-4F56-A51B-16D04C3D261EQ34296337-33FA690E-9FB5-4F03-AC39-FE61F0977340Q34398374-408C1DA6-AB28-4FD3-AFD9-F87CC73932C4Q34583970-B9B8765E-94BB-446D-B8C0-EB96CC780DA6Q34614091-5A375EB4-6401-4D71-B0BB-5853468C371AQ35170050-B3F28FB1-1FE1-49F7-BC51-FAFC2CF2E59BQ35227218-7ADBA765-43AC-4D64-8CBA-03882C22509FQ35629195-1F534C38-B344-4E81-9630-F7EC56760E9CQ35680023-4F6F6F2D-D6CF-407D-B5D1-9391F5A5792AQ35739625-8D25AF88-BCFB-4406-A751-A787C8E870A6Q35957506-40BEA805-5FDA-448A-993C-98BFD86F45C6Q35994587-839BDBA8-8A25-46CE-AD73-FC899F9549F6Q36106681-5463C90E-4518-4442-9749-9161B913CADFQ36278027-196AEC25-504F-4DBB-A1D9-C9976FA9A285Q36749750-FC6EE0C5-8FF1-47D0-889F-59680416C1CDQ36954468-362CB18C-A813-47E6-A52F-752255F26B82Q36975931-AAF78C7E-57C1-49BE-AB2A-F808E49C695BQ37039335-83A3149A-48CC-41AD-90A4-B7AC37381460Q37333073-B3084E2C-9797-482D-B4E5-FFCF3DF8EEAEQ37364343-03F1FEE0-5D03-4ADE-AD38-4036E78BD5B9Q37635735-BF0CF915-946F-4887-A358-13C993E79A82Q37662690-2362DD1E-BD2D-4D27-9611-05670F182AF8Q38016902-A3E3F8F7-00A4-4E80-8353-713B7122F85AQ38050398-F1C7ED5C-F208-43EB-9491-5480F16A2B3DQ38064420-465A9360-FFD3-40AE-85AA-61DF34A4F4D2
P2860
Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Rituximab specifically deplete ...... del of inflammatory arthritis.
@ast
Rituximab specifically deplete ...... del of inflammatory arthritis.
@en
type
label
Rituximab specifically deplete ...... del of inflammatory arthritis.
@ast
Rituximab specifically deplete ...... del of inflammatory arthritis.
@en
prefLabel
Rituximab specifically deplete ...... del of inflammatory arthritis.
@ast
Rituximab specifically deplete ...... del of inflammatory arthritis.
@en
P2093
P2860
P356
P1476
Rituximab specifically deplete ...... del of inflammatory arthritis.
@en
P2093
Christophe Benoist
Diane Mathis
Haochu Huang
P2860
P304
P356
10.1073/PNAS.1001074107
P407
P577
2010-02-22T00:00:00Z